Erythropoietin (EPO) and granulocyte colonystimulating factor (G-CSF) are likely to play broad roles in the brain. We investigated the effects of combination therapy with EPO and G-CSF in hypoxicischemic brain injury during the acute, subacute, and chronic phases. A total of 79 C57BL/6 mice with hypoxic-ischemic brain injury were randomly assigned acute (days 1-5), subacute (days 11-15) and chronic (days 28-32) groups. All of them were treated with G-CSF (250 μg/kg) and EPO (5 000 U/kg) or saline daily for 5 consecutive days. Behavioral assessments and immunohistochemistry for angiogenesis, neurogenesis, and astrogliosis were performed with an 8-week follow-up. Hypoxia-inducible factor-1 (HIF-1) was also measured by Western blot analysis. The results showed that the combination therapy with EPO and G-CSF in the acute phase signifi cantly improved rotarod performance and forelimb-use symmetry compared to the other groups, while subacute EPO and G-CSF therapy exhibited a modest improvement compared with the chronic saline controls. The acute treatment signifi cantly increased the density of CD31 + (PECAM-1) and α-smooth muscle actin + vessels in the frontal cortex and striatum, increased BrdU + /PSA-NCAM + neurogenesis in the subventricular zone, and decreased astroglial density in the striatum. Furthermore, acute treatment significantly increased the HIF-1 expression in the cytosol and nucleus, whereas chronic treatment did not change the HIF-1 expression, consistent with the behavioral outcomes. These results indicate that the induction of HIF-1 expression by combination therapy with EPO and G-CSF synergistically enhances not only behavioral function but also neurogenesis and angiogenesis while decreasing the astroglial response in a timedependent manner.
INTRODUCTION
Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) are likely to play broad roles in the central nervous system as well as the blood-forming system because receptors for both are expressed in the brain [1] [2] [3] .
EPO is the major growth regulator of the erythroid cell lineage, and its main biological function is to regulate the proliferation, maturation, and survival of erythroid Neurosci Bull February 1, 2014, 30(1): 107-117 108 progenitor cells in the bone marrow [4] . It is also a promising candidate drug for various neurological diseases [5] . Its beneficial effects have been attributed to a multitude of neuroprotective mechanisms, including anti-apoptosis, anti-oxidant actions, and restoration of blood-brain barrier integrity, as well as stimulation of neurogenesis and angiogenesis [6] [7] [8] . However, EPO treatment of patients with ischemic stroke has recently failed in a double-blind, randomized clinical trial, although preclinical findings and a clinical pilot study suggested that recombinant human EPO has beneficial effects [9, 10] . Therefore, the EPO and other neuroprotective or neurotrophic agents need to be combined to produce the optimal functional recovery.
G-CSF is a humoral factor affecting the survival, proliferation, and differentiation of hematopoietic cells [11, 12] .
G-CSF has been approved for the prevention and treatment of chemotherapy-induced neutropenia and apheresis in hematopoietic transplantation to mobilize bone marrow cells into systemic circulation [13, 14] . It has also been shown to exhibit several benefi cial effects in animals with stroke [14] [15] [16] .
In particular, it improves functional recovery after stroke even when the treatment is initiated after a delay [17] .
Recent studies reported that G-CSF upregulates EPO expression via the induction of hypoxia-inducible factor-1 (HIF-1) activity and that combination therapy of G-CSF and EPO synergistically enhances neuronal survival and angiogenesis in animal models of cerebral ischemia [18, 19] .
As a regulatory gene, HIF-1 controls critical pro-angiogenic genes such as vascular endothelial growth factor (VEGF) and EPO [20, 21] . G-CSF has been shown to enhance HIF-1 activity. Activated HIF-1 binds to the EPO promoter to turn on EPO expression [22] . Both EPO and G-CSF have been shown to possess angiogenic and neuroprotective properties [23] [24] [25] , and are regarded as therapeutic agents in acute stroke models [25, 26] . However, there is no evidence on the therapeutic time-window of EPO and G-CSF. Therefore, this study investigated the effects of EPO and G-CSF combination therapy on functional recovery in a mouse model of hypoxic-ischemic brain injury during the acute, subacute, and chronic phases.
MATERIALS AND METHODS

Animals
Seventy-nine male C57BL/6 mice at 12 weeks of age were All animals were maintained in a temperature-controlled animal care facility according to the animal protection regulations. All efforts were made to minimize suffering and the number of animals used.
Animal Grouping and Treatment
After induction of hypoxic-ischemic brain injury, mice were randomly assigned to the acute saline (n = 8), acute EPO + G-CSF (n = 9), subacute saline (n = 7), subacute EPO + G-CSF (n = 7), chronic saline (n = 6), and chronic EPO + G-CSF (n = 6) groups for behavioral assessment and immunohistochemistry at 8 weeks post-treatment. In addition, the other mice were equally allocated to the groups (n = 3 each) for immunohistochemistry at 2 weeks post-treatment, and for Western blot analysis the day after completion of 5-day EPO+G-CSF treatment. The mice received subcutaneous injections of 5 000 U/kg of recombinant human EPO and 250 μg/kg of recombinant human G-CSF, or saline once daily for 5 consecutive days (acute phase, days 1-5; subacute phase, days 11-15; chronic phase, days 28-32) . These doses were based on a previous report that each has a suffi cient effect [19] .
Before hypoxic-ischemic brain injury, additional 16 mice were also recruited as a no brain injury group to provide a more comprehensible understanding of the extent of functional recovery. A schematic timeline of this experiment from surgery to 8 weeks post-treatment is provided in Fig. 1A .
Rotarod Performance
A rotarod test was used to assess motor coordination and balance. All animals received a pre-treatment performance evaluation the day after surgery, and at 2, 4, 6 and 8 weeks after treatment, using an acceleration (4-80 rpm)
paradigm. The latency to fall from the rod was measured twice during each test, and individual tests were terminated at a maximum latency of 300 s.
Forelimb-use Asymmetry Test
To evaluate functional asymmetry resulting from the unilateral brain lesion, the cylinder test and the ladderwalking test were performed at 8 weeks post-treatment.
In the cylinder test, the number of times each forelimb contacted the cylinder wall as the mouse reared on its hind limbs was evaluated over a period of 5 min. The percentage of cylinder wall contacts with the hemiplegic forelimb was evaluated by the following formula [28, 29] 
Statistical Analysis
Statistical analysis was performed using Statistical 
RESULTS
Combined Treatment with EPO and G-CSF in the Acute
Phase Improves Rotarod Performance
The rotarod test with acceleration (4-80 rpm) was performed bi-weekly. There was no significant difference among the groups in performance prior to treatment. Moreover, the acute EPO + G-CSF group exhibited a longer latency than the subacute EPO + G-CSF group (119.88 ± 5.06 s) at 8 weeks post-treatment (P = 0.022) (Fig.   1B ). On the other hand, the subacute EPO + G-CSF group exhibited a modest improvement compared to the chronic saline controls during 2-6 weeks post-treatment (P <0.05).
The performance of the chronic EPO + G-CSF group did not change throughout the experimental period (Fig. 1B) .
Acute Phase Treatment Attenuates Forelimb-use Asymmetry
In the cylinder test, the difference (∆) relative to the control group in the percentage of wall contacts with contralateral limb was higher in mice treated with EPO and G-CSF in the acute phase (14.50 ± 1.73%) than those treated in the subacute phase (5.17 ± 2.24%) and the chronic phase (−0.33 ± 3.83%) (F = 8.875, P = 0.002) (Fig. 1C) . In the ladder-walking test, mice treated in the acute phase (1.67 ± 0.33%) and the subacute phase (2.0 ± 0.68%) showed a significant reduction in the difference (∆) relative to the control group in the percentage of slips among total steps with the hemiplegic forelimb compared to mice treated in the chronic phase (−0.50 ± 0.50%) (F = 6.678, P = 0.008).
We also calculated the ratio of motor function (%) relative (Fig. 1D) . Taken together, the cylinder and ladder walking performance results suggested that only the acute EPO + G-CSF group had a significant attenuation of the forelimbuse asymmetry, while the subacute EPO + G-CSF group showed modest improvement compared to saline controls.
Acute Phase Treatment Signifi cantly Increases Vessel Density
To determine the endogenous angiogenesis and arteriogenesis, blood vessels were quantified in both the frontal cortex and the striatum. CD31
endothelial cell densities in the frontal cortex and the striatum were higher in the acute EPO + G-CSF group than in the other groups at 2 weeks (frontal cortex F = 7.340, P <0.001; striatum F = 9.350, P <0.001) and 8 weeks posttreatment (frontal cortex F = 5.907, P = 0.001; striatum F = 7.421, P <0.001) ( Fig. 2A-C) . The subacute EPO + G-CSF group also showed a tendency to increase CD31 + endothelial cell density in the striatum but not in the frontal cortex.
Particularly, they showed an increase compared to the chronic EPO + G-CSF group and saline controls at 8 weeks post-treatment (P <0.05) ( Fig. 2A-C) . On the other hand, α-SMA + vessel density in the frontal cortex was increased in the acute EPO + G-CSF group compared to the other groups at 8 weeks post-treatment (F = 9.412, P <0.001), and that of the striatum also increased relative to the subacute and chronic groups (F = 3.589, P = 0.012) (Fig. 2D−F) . The results suggest that combination therapy of EPO and G-CSF during the acute phase increases arteriogenesis in addition to angiogenesis in the frontal cortex and the striatum.
Acute Phase Treatment Increases Neuronal Density
To determine the endogenous neurogenesis and neurallineage cell density, the expression of neural markers was assessed in both the SVZ and the striatum. βII-tubulin (Fig. 3C ). On the other hand, newly-generated cells stained with BrdU were higher in the acute EPO + G-CSF group than the other groups at 2 weeks (F = 9.488, P <0.001), but not at 8 weeks (Fig.   3D ). When PSA-NCAM, an early neuronal and migrating neuroblast marker, was co-stained with BrdU, the number of BrdU + /PSA-NCAM + cells in the SVZ was also greater in the acute EPO + G-CSF group than in the other groups at 2 weeks post-treatment (F = 10.125, P <0.001) (Fig. 3E, F ).
Combined Treatment with EPO and G-CSF Decreases Astroglial Density
To assess endogenous astrogliosis, GFAP, an astrocyte marker, and CS-56, a glial scar marker, were stained in the striatum. GFAP expression in the acute EPO + G-CSF group was lower than that in the acute saline group at 2 weeks post-treatment (P = 0.032) (Fig. 4A) . The subacute EPO + G-CSF group also showed a decrease in GFAP density compared to the subacute saline control (P <0.001) (Fig. 4A) . However, these differences did not persist to 8 weeks post-treatment. On the other hand, CS-56 expression in the acute EPO + G-CSF group was decreased compared to the acute saline group at 8 weeks post-treatment (P = 0.031) (Fig. 4B) . Taken together, mice treated with EPO and G-CSF in the acute and subacute phases showed a similar pattern of decreased GFAP expression in the neostriatum, suggesting that combination therapy with EPO and G-CSF reduces astroglial cell fate determination (Fig. 4C) .
HIF-1 Expression Increases in the Acute Phase Treatment Group
To measure the expression of HIF-1 after treatment in the three phases, Western blot analysis was performed. The acute EPO + G-CSF group showed an increase in HIF-1 expression compared to the other groups, except for the subacute EPO + G-CSF group in the cytosol (F = 3.968, P = 0.007) and in the nucleus (F = 2.483, P = 0.048). The subacute EPO + G-CSF group also had a clear tendency for increased HIF-1 expression in the cytosol and nucleus compared to the respective saline group. Moreover, total HIF-1 expression increased in the acute phase after combination therapy compared to the other groups, including the subacute EPO + G-CSF group (F = 3.537, P = 0.012). On the other hand, the chronic EPO + G-CSF group did not differ from the respective saline group (Fig. 5) . 
DISCUSSION
EPO affects the properties of endothelial cells in culture, such as proliferation and motility, and is associated with neovascularization as an angiogenic factor [30] . G-CSF has also been shown to induce an angiogenic response in endothelial cells as well as endothelial cell growth, and enhances arteriogenesis in ischemic stroke [31, 32] . Moreover, a recent study has shown that EPO and G-CSF together synergistically enhance angiogenesis and arteriogenesis to promote tissue plasticity [19] . The aim of this study was to investigate the particular time-window of the effects, rather than the effi cacy, of the combination therapy.
In this study, we also evaluated the peripheral human EPO levels using ELISA in each treatment group, and found a clear elevation in peripheral blood 1 day after the fi nal injection (day 5 of injection) whereas human EPO was almost undetectable in the control group treated with saline, confi rming systemic action by the subcutaneous injection of the growth factors (Fig. S1 ).
Consistent with previous fi ndings that the combination therapy of EPO and G-CSF promotes angiogenesis and functional recovery in ischemic models [19] , we showed significant improvements in behavioral performance weeks. These results are consistent with previous fi ndings that proliferation of neural progenitor cells residing in the ipsilateral SVZ following ischemic injury or following the treatment returned to near control level 2-4 weeks later [3, 19, 33, 34] .
In the present study, combination therapy with EPO and G-CSF during the acute and subacute phases significantly decreased GFAP + astroglial density at 2 weeks post-treatment, and acute treatment decreased CS-56 expression in the damaged striatum at 8 weeks.
In response to central nervous system injury, astrocytes change their morphology, proliferate, and migrate to the injury site to form a scar. These reactive astrocytes display hypertrophic morphology and express high levels of GFAP [35] . The glial scar forms a physical barrier to neurite outgrowth and produces infl ammatory mediators that cause further tissue damage [36] [37] [38] [39] . Accordingly, reducing scar formation has been suggested to overcome the physical barrier to axonal growth. Reactive astrocytes also have an unintended toxic effect by inducing glutamate release that augments neuronal death in the acute phase after hypoxicischemic brain injury, which causes the coincidence of hypoxia and inflammation [40] . In contrast, EPO is known to increase the level of neurogenesis while decreasing the glial response, favoring a neurogenic response in the damaged striatum after neonatal stroke [34] . Therefore, the shift of direct cell fate from astrogliosis toward neurogenesis shown in this study might be associated with long-term behavioral outcomes and functional improvement, as suggested in previous studies [40, 41] .
EPO and its receptor system with HIF-1-responsive proteins stimulate red blood cell production to increase O 2 transport in the blood and O 2 supply to the brain [42] .
The HIF-1 expression is able to act as a mechanism for neural plasticity [43, 44] . A recent study reported that G-CSF upregulates EPO expression via the induction of HIF-1 activity and the translocation of HIF-1 into the nucleus.
Consequently, neurogenesis and angiogenesis enhanced by HIF-1 activity contribute to functional recovery [18, 19] .
Similarly, our results showed that the acute-phase treatment induced HIF-1 expression in the cytosol and nucleus compared with the other groups, whereas the chronic-phase treatment did not make any difference. This fi nding is clearly related to the functional recovery after the combination therapy with EPO and G-CSF.
As a limitation of this study, this experiment designed saline groups as the only controls during the different periods, and the effect of EPO alone or G-CSF alone was not evaluated as positive control groups. Since a previous study already determined that combination therapy with EPO and G-CSF synergistically enhances functional recovery [19] , we mainly focused on the time-window of the effect by this therapy.
In conclusion, the results of this study suggest that combination therapy with EPO and G-CSF produced functional recovery in a mouse model of hypoxic-ischemic Moreover, acute phase treatment might contribute more to functional recovery than chronic-phase treatment in hypoxic-ischemic brain injury.
SUPPLEMENTAL DATA
